Altamira Therapeutics

Altamira Therapeutics We are addressing unmet medical needs with a focus on RNA therapeutics, allergies, viral infections and inner ear disorders.

03/14/2024

Altamira Therapeutics aims to break barriers in cancer treatment with our innovative candidate AM-401. AM-401 stops the "beating heart" of tumors, knocking down various KRAS mutations with polyKRASmut OligoPhore™ nanoparticles to inhibit cell proliferation in KRAS driven colorectal, pancreatic, or non-small cell lung cancer.

Key differentiating factors of AM-401:
- polyKRASmut allows for the targeting of different mutations and is thus polyvalent
- Blocking production of KRAS by degrading mRNA to cause less resistance than inhibition of KRAS
- Small molecule inhibitors have significant side effects, particularly when combined with other agents (OligoPhore™ targets specifically tumor cells)

More on AM-401: https://bit.ly/3JjIBix

Altamira Therapeutics has demonstrated extensive proof of concept. Our OligoPhore™ / SemaPhore™ platforms have been succ...
03/12/2024

Altamira Therapeutics has demonstrated extensive proof of concept. Our OligoPhore™ / SemaPhore™ platforms have been successfully tested in vivo in 17 different disease models, including KRAS-driven cancers and rheumatoid arthritis. Discover our solution to developing therapeutics for unmet medical needs: https://bit.ly/3ZH0E7G

The heart of Altamira Therapeutics' mission is to develop a solution for unlocking the full potential of RNA therapeutic...
03/07/2024

The heart of Altamira Therapeutics' mission is to develop a solution for unlocking the full potential of RNA therapeutics. We are driving forward transformative advancements with our OligoPhore™ / SemaPhore™ platforms for the delivery of nucleic acid payloads such as siRNA and mRNA into target cells, using systemic or local administration.

OligoPhore™ / SemaPhore™ are based on a proprietary 21 amino acid peptide that rapidly condenses peptide and nucleotide components into a polyplex. The polyplex has a size, charge, and other physical features that allow it to escape hepatic clearance and thus to reach other target tissues than the liver.

Explore the science behind our technology: https://bit.ly/3ZH0E7G

03/05/2024

AM-411 is Altamira Therapeutics' groundbreaking candidate for the treatment of rheumatoid arthritis. An intraveneously administered nanoparticle based on the OligoPhore™ platform, AM-411 targets p65, one of the main transcriptional regulators of the NF-kB pathway and a key checkpoint in RA inflammation

What are the key differentiating factors of AM-411?
- Reduced systemic side effects: Mediators of inflammation play many physiological roles in healthy tissues – AM-411 targets only inflamed tissues
- Less likelihood of resistance: Blocking production of an NF-κB component by degrading mRNA to cause less resistance than inhibition of NF-κB

Discover more as Altamira hopes to transform treatment paradigms for patients battling RA: https://bit.ly/3JjIBix

Altamira Therapeutics is revolutionizing the development of peptide-based nanoparticle technologies for efficient RNA de...
02/29/2024

Altamira Therapeutics is revolutionizing the development of peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues with its OligoPhore™ / SemaPhore™ platforms.

We currently have two flagship siRNA programs using our proprietary delivery technology: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. The versatile delivery platform is also suited for mRNA and other RNA modalities and made available to pharma or biotech companies through out-licensing.

Learn more about our flagship programs using Altamira's proprietary delivery technology: https://bit.ly/3JjIBix

How do our OligoPhore™ / SemaPhore™ platforms work? OligoPhore/SemaPhore are nanoparticles comprising a proprietary pept...
02/27/2024

How do our OligoPhore™ / SemaPhore™ platforms work? OligoPhore/SemaPhore are nanoparticles comprising a proprietary peptide + RNA payload designed to enable safe and effective delivery by systemic administration.

Several key features of our technology include:
- High stability
- Extrahepatic delivery
- Efficient endosomal escape
- High selectivity
- Safety

More on our science: https://bit.ly/3ZH0E7G

The global rheumatoid arthritis market value is expected to reach $62.9 billion in 2027. Altamira Therapeutics is tappin...
02/15/2024

The global rheumatoid arthritis market value is expected to reach $62.9 billion in 2027. Altamira Therapeutics is tapping into this growing market with AM-411, our intravenously administered nanoparticle which aims to reduce the inflammation present in individuals with RA.

More on our key differentiating factors: https://bit.ly/3JjIBix

Last month, Altamira Therapeutics filed a second provisional patent application for OligoPhore™ nanoparticles targeting ...
02/13/2024

Last month, Altamira Therapeutics filed a second provisional patent application for OligoPhore™ nanoparticles targeting different KRAS mutations in cancer treatment.

Although the role of KRAS mutations in cancer has been known for decades, they have remained a challenging target for therapeutic interventions. KRAS was long considered undruggable, in part, because of the lack of obvious binding sites. Only recently, the FDA approved the first two treatments for KRAS-driven cancer: sotorasib and adagrasib, two small molecule inhibitors of G12C-mutated KRAS for the treatment of NSCLC.

We look forward to advancing our AM-401 program to provide clinicians and patients with a comprehensive treatment option for KRAS-driven cancers: https://bit.ly/3HwrVmw

A recently published study by an independent research group shows enhanced cell transduction with adeno-associated virus...
02/12/2024

A recently published study by an independent research group shows enhanced cell transduction with adeno-associated virus (AAV) vectors, commonly used in gene therapy, when integrating Altamira’s peptide-based delivery technology.

“The study results once again highlight the strong capability of our technology to promote the release of nucleic acids from the endosome into the cytoplasm, which has remained a key limiting factor for both non-viral vectors and viral-derived delivery vehicles such as AAVs,” commented Covadonga Pañeda, Ph.D., Altamira Therapeutics’ Chief Operating Officer. “Better transduction efficiency means that lower doses of AAVs may be used, which could lower the risk for deleterious immune responses and increase the safety of AAV-based vectors. In addition, the integration of the p5RHH peptide into different serotypes of AAV vectors may open new possibilities in AAV-based gene therapy in cells and tissues that are not typically amenable to AVV transduction.”

“Melittin analog p5RHH enhances recombinant adeno-associated virus transduction efficiency” is now in the Journal of Integrative Medicine. More details here: https://bit.ly/3ST0ABy

An independent research group recently published a peer-reviewed article in the Journal of Integrative Medicine titled “...
02/08/2024

An independent research group recently published a peer-reviewed article in the Journal of Integrative Medicine titled “Melittin analog p5RHH enhances recombinant adeno-associated virus transduction efficiency". This work evaluates the use of various peptides to enhance adeno-associated virus (AAV) cell transduction.

More details here: https://bit.ly/3ST0ABy

02/08/2024

Altamira Therapeutics hopes to revolutionize therapy for patients with KRAS-driven cancers, such as pancreatic, colorectal, and non-small cell lung cancer, with our AM-401 program.

Why AM-401 is a game-changer:
- Targets the root cause: Unlike traditional therapies that target specific mutations, AM-401 silences the KRAS gene itself, regardless of the specific mutation present. This "polyvalent" approach holds immense promise for tackling a broader spectrum of KRAS-driven cancers.
- Precision delivery: AM-401 utilizes Altamira's proprietary OligoPhore™ platform, a nanoparticle delivery system that navigates the body's treacherous terrain to deliver its payload directly to tumor cells. This targeted approach minimizes harm to healthy tissues and potentially reduces side effects.
- Early promise: Preclinical studies have shown AM-401 to be highly effective in shrinking tumors and extending survival in KRAS-driven cancer models.

Explore the science behind AM-401: https://bit.ly/3JjIBix

Altamira Therapeutics’ (Nasdaq: CYTO) peptide-based delivery platform shown to enhance potency of commonly used gene del...
02/07/2024

Altamira Therapeutics’ (Nasdaq: CYTO) peptide-based delivery platform shown to enhance potency of commonly used gene delivery method as published in peer-reviewed journal (Journal of Integrative Medicine). The article titled "Melittin analog p5RHH enhances recombinant adeno-associated virus transduction efficiency" evaluates the use of various peptides to enhance adeno-associated virus (AAV) cell transduction and was conducted by an independent research group.

Read the press release here: https://bit.ly/3ST0ABy

Address

8 The Green Suite 12455
Dover, DE
19901

Website

Alerts

Be the first to know and let us send you an email when Altamira Therapeutics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category